Remove 2004 Remove Compounding Remove FDA
article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid. Patent & Trademark Office granted two more patents, but did not do so until 2008. One expires next year and the other in 2027, well beyond the original patent expiration date.

FDA 120
article thumbnail

Diabetes Risk Reduction Practices Low for Women With Gestational Diabetes

Drug Topics

They included patients from a large regional hospital in northern Victoria, Australia, who attended the diabetes center from July 2004 to July 2005 for the management of gestational diabetes. The pilot study was aimed at determining diabetes risk reduction behavior when achieving a healthy weight and being physically active.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few? 3 Is two too few?

FDA 103
article thumbnail

NITROSAMINES: Where now?

European Pharmaceutical Review

The US Food and Drug Administration (FDA) subsequently developed a liquid chromatography – high resolution mass spectroscopy (LC-HRMS) method for the determination of NDMA in ranitidine. FDA assigned a provisional AI of 26.5 10 It is not clear whether FDA will adopt a similar t-AI. This t-AI would be used for ≤12 months.

FDA 98
article thumbnail

API nitrosamines: method sensitivity issues

European Pharmaceutical Review

The European Medicines Agency (EMA) advocates 18 ng/day 6 as the default AI, where the US Food and Drug Administration (FDA) supports a value of 26.5 8 As such, detection of an API nitrosamine with an MDI of 4000 mg/day may be feasible for FDA submissions, but probably not with the EMA. ng/day for novel API nitrosamines. 25 June 2020.

Dosage 59
article thumbnail

Nitrosamine drug substance-related impurities (NDSRIs)

European Pharmaceutical Review

The US Food and Drug Administration (FDA) requires that manufacturers establish whether nitrosamines, including NDSRIs, could be present in active pharmaceutical ingredients (APIs) and drug products, using the “three-step mitigation strategy described in the agency’s guidance”. Nitrosamine Imp -Q&A-Mar-22.pdf. Accessed on 02 April 2022.

FDA 52
article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

Meloxicam injection (Xifyrm; Azurity Pharmaceuticals, Inc) received FDA approval for use in adults for the management of moderate-to-severe pain, either alone or in combination with non-steroidal anti-inflammatory drug (NSAID) analgesics.

FDA 73